20-Aug-2026
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Business Wire (Wed, 5-Aug 4:15 PM ET)
Lipocine Appoints Michael J. Grissinger to Board of Directors
PRNewswire (Mon, 3-Aug 8:00 AM ET)
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
Business Wire (Tue, 21-Jul 4:00 PM ET)
Adicet Bio Sees Reduced Losses and Lower Spending as Key Clinical Milestones Near
Market Chameleon (Thu, 14-May 7:50 AM ET)
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Adicet Bio trades on the NASDAQ stock market under the symbol ACET.
As of August 20, 2026, ACET stock price declined to $9.38 with 60,425 million shares trading.
ACET has a beta of 1.68, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.09 to the broad based SPY ETF.
ACET has a market cap of $87.81 million. This is considered a Micro Cap stock.
In the last 3 years, ACET traded as high as $60.32 and as low as $6.01.
The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.
ACET has underperformed the market in the last year with a return of -11.2%, while SPY returned +20.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ACET shares. However, ACET has outperformed the market in the last 3 month and 2 week periods, returning +29.4% and +2.4%, while SPY returned +4.2% and -0.9%, respectively. This indicates ACET has been having a stronger performance recently.
ACET support price is $9.07 and resistance is $9.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.
